Blog Home Page (News)

Home/Blog Home Page (News)
Blog Home Page (News)2021-04-19T13:28:07-04:00

The NFXF Blog

SUBSCRIBE

Research Updates and a Chicago Chapter

By |May 8, 2018|

On May 5, the Greater Chicago Fragile X Group held a Research Update featuring Dr. Elizabeth Berry-Kravis. Participants in the meeting heard from Dr. Elizabeth Berry-Kravis as she shared information about current areas of research into [...]

Zynerba Pharmaceuticals Announces Oral Presentation of ZYN002 Data at the 16th NFXF International Fragile X Conference in July 2018

By |Apr 24, 2018|

PRESS RELEASE FROM ZYNERBA PHARMACEUTICALS Devon, PA, , April 23, 2018 — Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty neuropsychiatric pharmaceutical company dedicated to developing and commercializing innovative pharmaceutically-produced transdermal cannabinoid treatments for rare and near-rare neurological and [...]

A note to all of our volunteers

By |Apr 18, 2018|

*Actual Linda Sorensen not shown I have always been in awe of the strength and courage of each of you.  I know life with Fragile X isn’t easy, and making a commitment to [...]

Fragile X Awareness Happens All Year

By |Apr 10, 2018|

Fragile X awareness is a 365-day-a-year job, which is why it is one of our core pillars. But, we set aside July every year as a month to help raise awareness of Fragile X, and [...]

A Fun Moms’ Night Out!

By |Apr 9, 2018|

Five moms met in East Windsor, CT on March 14th where they shared a meal, talked about housing, getting ready for adult services and had all around a lot of fun! One of the most [...]

CDC Funding for Fragile X – Coalition Letter

By |Apr 9, 2018|

There is strength in numbers, which is why we work with other patient advocacy groups on common goals, such as funding at the National Institutes of Health (NIH), the Centers for Disease Control and Prevention [...]

Potential FXS Drug Receives Orphan Drug Status

By |Apr 4, 2018|

Yesterday, the drug BPN14770, which is in development for possible treatment of Fragile X syndrome, was granted orphan drug status by the FDA. As the patient advocacy organization for Fragile X, the NFXF will be [...]